Download to read offline
![DR KANHU CHARAN PATRO
M.D, D.N.B[RT], MBA, FICRO, FAROI, PDCR, CEPC
www.slideshare.net/search/slideshow?searchfrom=header&q=oncology+cartoons
www.facebook.com/oncologycartoons/photos_albums
117th
Volume/DECEMBER 2025
ONCOLOGY CRATOONS EDUCATIVE E-BOOK](https://image.slidesharecdn.com/dec2025-251205004709-73382b38/75/DEC-2025ONCOLOGY-CARTOONS-BY-DR-KANHU-CHARAN-PATRO-1-2048.jpg)
Uploaded byKanhu Charan
DEC 2025ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
DEC 2025ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
More Related Content
Similar to DEC 2025ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
More from Kanhu Charan
DEC 2025ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
- 1. DR KANHU CHARANPATRO M.D, D.N.B[RT], MBA, FICRO, FAROI, PDCR, CEPC www.slideshare.net/search/slideshow?searchfrom=header&q=oncology+cartoons www.facebook.com/oncologycartoons/photos_albums 117th Volume/DECEMBER 2025 ONCOLOGY CRATOONS EDUCATIVE E-BOOK
- 4. DIAGNOSTIC CRITERIA FORTUMOR LYSIS SYNDROME 16th NOV 2025/ CHEMO R. Gregory Bociek/NEJM/2025
- 5. Pathophysiology of TumorLysis Syndrome 17th NOV 2025/ CHEMO R. Gregory Bociek/NEJM/2025
- 6. Tumor Lysis Commonlyseen in Cancers & Therapies 18th NOV 2025/ CHEMO R. Gregory Bociek/NEJM/2025
- 7. Indications for PMRTASTRO-ASCO-SSOguideline 19th NOV 2025/ BREAST RJimenez et al /JCO/2025
- 8. PMRT Guidanceon Target Coverage 20th NOV 2025/ BREAST RJimenez et al /JCO/2025
- 9. PMRTGuidance on OARconstraints 21st NOV 2025/ BREAST RJimenez et al /JCO/2025
- 10. 15 years ofProtecT study- prostate 22nd NOV 2025/ PROSTATE Jenny L. Donovan/NEJM/2023
- 11. 12 years ofProtecT study- prostate- complications 23rd NOV 2025/ PROSTATE F.C. Hamdy/NEJM/2025
- 12. Durvalumab in lungcancers important studies 24th NOV 2025/ LUNG Collection
- 13. (PACIFIC-1) maintenance Durvalumabin stag. lll NSCLC after CTRT 25th NOV 2025/LUNG Jeffrey D. Bradle/JCO/2025
- 14. (PACIFIC-2)Conc.CTRT+Durvalumab in stag.lll NSCLC 26th NOV 2025/LUNG Jeffrey D. Bradle/JCO/2025
- 15. (PACIFIC-R) Durvalumab inNSCLC Real world data 27th NOV 2025/LUNG A. R. Filippi/ESMO OPEN/2023 Parameter Result Study type Real-world, retrospective, 1154 patients Median fup 38.7 months Median OS Not reached 2-year OS 72.3% 3-year OS 63.2% Median PFS 24.1 months 2-year PFS 50.1% 3-year PFS 42.2% PD-L1 ≥1% (3-yr OS) 67.0% PD-L1 <1% (3-yr OS) 54.4% cCRT (3-yr OS) 64.8% sCRT (3-yr OS) 57.9% Durva ≤42 days (3-yr OS) 66.0% Durva >42 days (3-yr OS) 61.8% Non-squamous (3-yr OS) 68.0% Squamous (3-yr OS) 53.2% TTDM – median 35.5 months TDLR – median Not reached TFST – median 35.9 months
- 16. (PACIFIC - 6)CTRT seq. Durvalumab in stag. lll NSCLC 28th NOV 2025/LUNG Jeffrey D. Bradle/JCO/2025 Parameter Key Findings Grade 3–4 AEs (any cause) 27.4% Grade 3–4 treatment-related AEs (PRAEs) 6.0% Any-grade pneumonitis 18.8% Grade 3–4 pneumonitis 1.7% Fatal AEs (any cause) 2.6% (1 death due to pneumonitis) Discontinuation due to AEs 27.4% Most common AEs (any grade) Cough (38.5%), Fatigue (20.5%), Dyspnea (24.8%), Pneumonitis (18.8%) Objective response rate (ORR) 20.5% Complete response 2.6% Partial response 17.9% Median PFS 13.1 months 2-year PFS rate 35.3% Median OS 39.0 months 3-year OS rate 56.5%
- 17. MOA DIFFERENCE BETWEENDURVALUMAB AND PEMBRO 29th NOV 2025/IMMUNO Jeffrey D. Bradle/JCO/2025
- 18. KEYNOTE -799 trialDESIGN 30th NOV 2025/LUNG Martin Reck-/JCO-8057/2025
- 19. 4 year outcomeof KEYNOTE -799 trial 1st DEC 2025/LUNG Martin Reck-/JCO-8057/2025
- 20. Durvalumab over Pembrolizumabin Stage III NSCLC 2nd DEC 2025/LUNG Dr Kanhu Charan Patro
- 21. SYSUCC-001 TRIAL –10-YEAR UPDATE – EXTENDED CAPECITABINE 3rd DEC 2025/BREAST Zan Hou/LANCET ONCOLOGY/2025 Clinical Implications & Takeaways 1. Durable DFS benefit: Extended metronomic Capecitabine reduces recurrence risk by 40% at 10 years in early TNBC 2. Biomarker-driven selection: FOXC1-high status identifies patients who derive the greatest DFS and OS benefit 3. Actionable strategy: Consider FOXC1 testing to prioritize extended capecitabine in appropriate patients 4. Safety profile: 1-year metronomic dosing (650 mg/m² twice daily) is manageable with appropriate monitoring 5. Future validation: Prospective studies needed to confirm FOXC1 predictive utility in non- Chinese TNBC cohorts 6. Extended 1-year metronomic capecitabine offers durable DFS benefit at 10 years in early TNBC. 7. OS improvement trends positive but does not reach significance. 8. FOXC1-high tumours appear to derive the greatest survival benefit, suggesting FOXC1 may help tailor adjuvant therapy. 9. Conclusions should be cautious because FOXC1 findings are exploratory and require validation.
- 22. Intraoperative Radiation Therapy(IORT) in Pancreatic Cancer 4th DEC 2025/PANCREAS AhmedElguindy/SEMINARS IN RADIATION ONCOLOGY/2025
- 23. Cardiac Safety ofUltra-Hypofractionated WBI 5th DEC 2025/BREAST VIOLA SALVESTRINI/ RADIOTHERAPY ONCOLOGY/2025
- 24. ESTRO–ASTRO Preoperative BreastRadiotherapy guideline 6th DEC 2025/BREAST ALICE ZAMAGNI/ RADIOTHERAPY ONCOLOGY/2025
- 25. STEREOTACTIC RADIOTHERAPY ONPARKINSONIAN TREMORS 7th DEC 2025/STEREOTAXY Laura M.M./ RADIOTHERAPY ONCOLOGY/2025
- 26. Adjuvant Olaparib inBRCA-mutated Early Breast Cancer 8th DEC 2025/BREAST A.N.J. Tutt/NEJM/2023
- 27. EFLORNITHINE (DFMO) INASTROCYTOMAS 9th DEC 2025/CHEMO GOOGLE
- 28. Eflornithine Plus LomustineVs Lomustine in Rec.Grade 3 Astro 10th DEC 2025/BRAIN Howard Colman/NeuroOncology/2025
- 29. OUTCOMES WITH ANTIDEPRESSANTUSE IN GLIOBLASTOMA 11th DEC 2025/BRAIN Yifei Sun/NeuroOncology/2025
- 30. Single # SRSvs Hypofractionated SRS (HSRS) for Large Meningiomas (>8 cc) 12th DEC 2025/BRAIN Bhavya Pahwa/ Journal of Neuro-Oncology/2025
- 31. UNDERSTANDING SPINAL MELANOCYTOMA 13th DEC2025/BRAIN Alice Ryba/ Journal of Neuro-Oncology/2025
- 32. RIGHT-SIDED vs LEFT-SIDEDCOLON CANCER 14th DEC 2025/COLORECTAL DR KANHU CHARAN PATRO
- 33. Lung Cancer orTB? Do Not Miss the Difference 15th DEC 2025/PUBLIC DR KANHU CHARAN PATRO